Fig 1.
Flow chart of the patient cohort selection.
Table 1.
Demographic and clinical characteristics of patients stratified by PSA level and GS.
Table 2.
Univariate and multivariate competing-risks regression analysis for PCSM.
Fig 2.
Cumulative incidence function of PCSM across groups.
Abbreviation: PCSM = prostate cancer-specific mortality.
Fig 3.
Top three most significant gene sets identified in GSEA of the GEO Cohort.
Abbreviation: GSEA = Gene set enrichment analysis, GEO = Gene Expression Omnibus, IGF = insulin-like growth factor, IGFR = insulin-like growth factor receptor, PI3K = phosphoinositide 3-kinase, NF-κB = nuclear factor-κB, EGF = epidermal growth factor, EGFR = epidermal growth factor receptor.
Fig 4.
Network visualization of enriched pathways based on GSEA results.
Abbreviation: GSEA = Gene set enrichment analysis, PRC = polycomb repressive complex, EGF = epidermal growth factor, ERBB2 = erythroblastic oncogene B 2, RAS = rat sarcoma virus, ERK = extracellular signal-regulated kinase, EGFR = epidermal growth factor receptor, PI3K = phosphoinositide 3-kinase, HIV = human immunodeficiency virus, TNF = tumor necrosis factor, NF-κB = nuclear factor-κB, GEF = guanine nucleotide exchange factor, GF = growth factor, RTK = receptor tyrosine kinase, NES = normalized enrichment scores.